Omaha, NEBRASKA10 Active Studies

Interstitial Cystitis Clinical Trials in Omaha, NEBRASKA

Find 10 actively recruiting interstitial cystitis clinical trials in Omaha, NEBRASKA. Connect with local research sites and explore new treatment options.

10
Active Trials
9
Sponsors
1,932
Enrolling

Recruiting Interstitial Cystitis Studies in Omaha

RecruitingOmaha, NEBRASKANCT06876649

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib....

787 participants
Eli Lilly and Company
View Study Details
RecruitingOmaha, NEBRASKANCT06876662

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-...

279 participants
Eli Lilly and Company
View Study Details
RecruitingOmaha, NEBRASKANCT02407028

Hyperbaric Oxygen Brain Injury Treatment Trial

The purpose of this innovative adaptive phase II trial design is to determine the optimal combination of hyperbaric oxygen treatment parameters that is most likely to demonstrate improvement in the ou...

200 participants
Hennepin Healthcare Research Institute
View Study Details
RecruitingOmaha, NEBRASKANCT05669833

Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients

The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients ...

150 participants
University of Pennsylvania
View Study Details
RecruitingOmaha, NEBRASKANCT06922591

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236 or...

133 participants
Tango Therapeutics, Inc.
View Study Details
RecruitingOmaha, NEBRASKANCT06524375

A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period.

The main purpose of the study is to evaluate if adding venetoclax to participants receiving cBTKi for the 1L CLL can achieve deep durable remissions of undetectable measurable residual disease \[uMRD ...

110 participants
Genentech, Inc.
View Study Details
RecruitingOmaha, NEBRASKANCT04222062

A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease

This study is being done to see if adding GLIADEL to the site where the tumor was removed works as well as just having the tumor removed with radiation treatment done within six weeks after the surger...

100 participants
University of Nebraska
View Study Details
RecruitingOmaha, NEBRASKANCT06637501

A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

The purpose of this study is to support the registration plan of sonrotoclax plus zanubrutinib treatment in participants with previously untreated CLL. This study is designed to assess the contributio...

87 participants
BeiGene
View Study Details
RecruitingOmaha, NEBRASKANCT03104491

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects ...

44 participants
Leland Metheny
View Study Details
RecruitingOmaha, NEBRASKANCT04889716

CAR-T Followed by Bispecific Antibodies

The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab (Cohort 1) or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically...

42 participants
Abramson Cancer Center at Penn Medicine
View Study Details

About Interstitial Cystitis Clinical Trials in Omaha

Interstitial cystitis/bladder pain syndrome is a chronic condition causing bladder pressure, bladder pain, and sometimes pelvic pain. It primarily affects women and can significantly impact quality of life. Treatment includes dietary changes, bladder instillations, oral medications, and neuromodulation.

There are currently 10 interstitial cystitis clinical trials recruiting participants in Omaha, NEBRASKA. These studies are seeking a combined 1,932 participants. Research is being sponsored by Eli Lilly and Company, Hennepin Healthcare Research Institute, University of Pennsylvania and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Interstitial Cystitis Clinical Trials in Omaha — FAQ

Are there interstitial cystitis clinical trials in Omaha?

Yes, there are 10 interstitial cystitis clinical trials currently recruiting in Omaha, NEBRASKA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Omaha?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Omaha research site will contact you about next steps.

Are clinical trials in Omaha free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Omaha studies also compensate for your time and travel.

What interstitial cystitis treatments are being tested?

The 10 active trials in Omaha are testing new therapies including novel drugs, biologics, and treatment approaches for interstitial cystitis.

Data updated March 2, 2026 from ClinicalTrials.gov